Monash Institute researchers target post menopause heart health with new grant

Researchers at the Monash Institute of Pharmaceutical Sciences are sharing in a pool of 14.5 million dollars in Heart Foundation funding to study cardiovascular health. Mirage News reported that Professor Rebecca Ritchie, the theme leader of Drug Discovery Biology at the institute, will lead a new project examining heart outcomes in women above a healthy weight. [1]

The research focuses specifically on how menopause alters the cardiovascular benefits of the weight loss medication Mounjaro. Mirage News noted that the study aims to evaluate treatment success by positioning menopause as a key biological factor in heart disease progression and pharmaceutical response. [1]

Professor Ritchie stated that hormonal changes occurring during menopause directly influence both the progression of heart disease and the effectiveness of available treatments. Mirage News reported that the study seeks to place women squarely at the center of medical discovery. [1]

The project forms part of a broader national push to fund targeted medical studies, alongside general initiatives supported by the Australian Government Department of Health, Disability and Ageing. The National Tribune also covered the news regarding the heart health research at the Monash Institute of Pharmaceutical Sciences. [1][3][6]